NYSE:TXMD
TherapeuticsMD Stock News
$2.22
+0.100 (+4.72%)
At Close: May 17, 2024
TherapeuticsMD Announces Issuance of a J-Code for ANNOVERA® to Be Utilized in the Public Health Sector
06:50am, Monday, 23'rd Aug 2021
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women's healthcare company, today announced that the Centers for Medicare and Medicaid Services (CMS) con
5 Penny Stocks Insiders Are Buying
08:01am, Thursday, 19'th Aug 2021
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their ove
TherapeuticsMD Announces Appointment of Hugh O'Dowd as President
04:30pm, Monday, 09'th Aug 2021
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women's healthcare company, today announced the appointment of Hugh O'Dowd as President. Mr. O'Dowd succe
TherapeuticsMD's (TXMD) CEO Rob Finizio on Q2 2021 Results - Earnings Call Transcript
11:57am, Wednesday, 04'th Aug 2021
TherapeuticsMD's (TXMD) CEO Rob Finizio on Q2 2021 Results - Earnings Call Transcript
TherapeuticsMD (TXMD) Reports Q2 Loss, Tops Revenue Estimates
09:10am, Wednesday, 04'th Aug 2021
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of 0.00% and 1.64%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Recap: TherapeuticsMD Q2 Earnings
07:15am, Wednesday, 04'th Aug 2021
Shares of TherapeuticsMD (NASDAQ:TXMD) moved higher by 4.1% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 42.11% year over year to ($0.11),
TherapeuticsMD Announces Second Quarter 2021 Financial Results
06:50am, Wednesday, 04'th Aug 2021
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women's healthcare company, today reported financial results for the se
TherapeuticsMD to Report Second Quarter 2021 Results on August 4, 2021
06:50am, Monday, 26'th Jul 2021
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women's healthcare company, today announced that it will report its second quarter 2021 financial results
TherapeuticsMD: The Long Road To Profitability
03:00pm, Thursday, 08'th Jul 2021
Although the market did not take favorably to recent Q1 numbers, there were some encouraging trends.
TherapeuticsMD Announces Submission of Low Dose BIJUVA® 0.5 mg/100 mg Supplemental New Drug Application to FDA
06:50am, Tuesday, 25'th May 2021
BOCA RATON, Fla.--(BUSINESS WIRE)--TXMD submits supplemental NDA to FDA for low-dose Bijuva
The Sun Sentinel Names TherapeuticsMD, Inc. a Winner of the South Florida Top Workplaces 2021 Award
07:00am, Monday, 24'th May 2021
BOCA RATON, Fla.--(BUSINESS WIRE)--Sun Sentinel names TXMD as Top Workplace Winner
TherapeuticsMD, Inc. (TXMD) CEO Rob Finizio on Q1 2021 Results - Earnings Call Transcript
01:45pm, Thursday, 06'th May 2021
TherapeuticsMD, Inc. (TXMD) CEO Rob Finizio on Q1 2021 Results - Earnings Call Transcript
TherapeuticsMD Shares Plunge On Declining Gross Margin, Total Prescription Volume
10:56am, Thursday, 06'th May 2021
TherapeuticsMD Inc (NASDAQ: TXMD) reported a Q1 EPS loss of $0.11 better than the analyst consensus estimate loss of $0.12, as well as an improvement from EPS loss of $0.21 a year ago. Sales of $1
TherapeuticsMD: Fighting To Regain Support Above $1.20
01:45pm, Wednesday, 21'st Apr 2021
Although sales grew by 30% in the fourth quarter, the market remains disinterested. ANNOVERA remains the key. Management are bullish on what is to come without restrictions in a post-covid world.
TherapeuticsMD: Great Product, But We Are Underwhelmed By Execution
09:37am, Wednesday, 21'st Apr 2021
TherapeuticsMD: Great Product, But We Are Underwhelmed By Execution
